ViewRay Inc. (VRAY) is up 5.74% in premarket trading today, trading at $7.00 at last check. ViewRay shares rose 0.91% on Tuesday to close at $6.62. VRAY shares were traded in volume of 0.62 million, which is lower than the average volume of 1.19 million over a 3-months period. On Tuesday, VRAY stock fluctuated between $6.42 and $6.66.

VRAY’s stock has gained 73.30% year-to-date, but has lost -1.34% in the previous five sessions. The 50-day moving average for the VRAY stock is $5.73, while its 200-day moving average is $4.54. The share price of VRAY stock has increased following the use of the company’s technology in a clinical study.

The VRAY technology has been tested by who?

MRIdian radiation therapy systems are designed, manufactured, and marketed by ViewRay. The MRIdian solution is built on VRAY’s proprietary high-definition MR imaging technology, specially developed for advanced radiation oncology workflow and challenges. While other MR systems in diagnostic radiology can exhibit issues such as beam distortion, skin toxicity, or other issues that may occur when high magnetic fields interact with radiation beams, MRIdian’s high-definition MR is purpose built to overcome these challenges. VRAY owns the trademarks ViewRay and MRIdian.

According to a press release by ViewRay today, the Miami Cancer Institute of Baptist Health South Florida enrolled the first patient in a clinical study.

• The “Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction for Inoperable Primary or Metastatic Carcinoma” is referred to as the SMART ONE trial.
• In this single-arm prospective study, led by Dr. Michael Chuong, it will be explored whether single-fraction stereotactic ablative body radiation therapy (SABR) could be an effective treatment.
• Study participants will be evaluated for primary or metastatic carcinomas affecting the liver, pancreas, kidney, adrenal gland, abdominal/pelvic lymph nodes, and lung.
• Chuong is a radiation oncologist and MD, FACRO, Medical Director at Miami Cancer Institute. He specializes in proton therapy and MR-guided therapy.
• SABR, including visualization of the internal anatomy before and continuously throughout treatment delivery, benefits from the use of MRI rather than CT for daily image guidance.

How helpful is VRAY’s technology?

By using VRAY’s MRIdian, clinicians can deliver ablative doses safely and apply single-fraction SABR to tumors previously unreachable. ViewRay (VRAY)’s technology includes diagnostic-quality anatomic imaging and continuous intrafraction visualization of the soft tissues during treatment prep, automatic beam gating to implement adaptive planning while treatment is being delivered. By enabling VRAY’s target volume planning features, including healthy tissue spared from dosing, higher-grade toxicities can be reduced or even eliminated, which are often associated with SABR dosing.